Compare Prudential PLC (PUK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Prudential PLC trades at $23.92 (market cap $28.84B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Prudential PLC is far larger — about 2.9× State Street SPDR S&P Biotech ETF's market cap, and Prudential PLC pays a 2.33% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PUK | XBI | |
|---|---|---|
Market Cap | $28.84B | $10.11B |
Volume | 3,531,298 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $33.61 | $169.55 |
52-Week Low | $23.54 | $104.99 |
Typical Hold Time | 119 Days | 38 Days |
Enterprise Value | $28.38B | — |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUK trades at $23.88, up 1.44% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company demonstrates strong fundamentals with $27.4B revenue, 14.52% net margin, and attractive valuation at 8.4 P/E ratio. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while maintaining consistent dividend payments.
PUK presents a value opportunity with solid profitability and growth trajectory, though near-term technical weakness and emerging market exit execution risks require monitoring. Analyst consensus leans positive with 50% buy ratings, supporting potential upside from current levels if operational improvements materialize as planned.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
